Eli Lilly Achieves Record High Success Rate in Clinical Trials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 15 2026
0mins
Source: NASDAQ.COM
- Clinical Trial Success Rate: Eli Lilly achieved positive outcomes in nearly all R&D key events in 2025, showcasing strong performance in diabetes and weight loss, which is expected to further drive the company's financial growth.
- Innovative Drug Progress: Eli Lilly's anti-obesity drug retatrutide excelled in a phase 3 study, potentially providing new revenue streams, while the cancer drug Jaypirca also succeeded in phase 3, paving the way for label expansions.
- AI Investment: Eli Lilly is investing in building the industry's largest AI supercomputer to accelerate drug development, indicating the company's forward-thinking approach to innovation, with the FDA also recognizing the value of AI in drug discovery.
- Strong Financial Performance: Eli Lilly not only excels in clinical trials but also continues to reward shareholders with growing dividends and share buybacks, demonstrating its diversified investment potential beyond diabetes and weight loss.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1125.270
Low
950.00
Averages
1192
High
1500
Current: 1125.270
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Becomes First $1 Trillion Pharmaceutical Company
- GLP-1 Drug Expansion: Eli Lilly's Mounjaro and Zepbound have driven a 56% year-over-year revenue increase to $19.8 billion in Q1, with earnings per share soaring 156% to $8.55, indicating robust market demand in diabetes and obesity treatment.
- Acquisition to Broaden Portfolio: Lilly announced a $3.83 billion acquisition of three biotech firms, gaining promising drug candidates, including a $1.5 billion purchase of Curevo for a shingles vaccine, enhancing its product lineup significantly.
- Multiple Indication Development: While GLP-1 drugs are in the spotlight, Lilly's immunology, oncology, and neuroscience therapies saw a 160% revenue increase in Q1, with 42 phase 3 trials underway, anticipating several new therapies to launch soon.
- Strong Market Expectations: Lilly shares trade at a premium valuation of around 29 times projected earnings, reflecting expectations of sustained strong demand for GLP-1 drugs, with projected 2026 revenue between $82 billion and $85 billion, marking a 28% increase.
See More
Eli Lilly Accelerates Diversification Strategy with New Acquisitions
- New Asset Acquisitions: Eli Lilly's recent acquisitions of Curevo, LimmaTech Biologics, and Vaccine Company, with a total expected expenditure of up to $3.8 billion, will enhance its asset portfolio in infectious diseases, thereby reducing reliance on its core market.
- Strong Financial Performance: Over the past three years, Eli Lilly's free cash flow has significantly increased, partly due to its success in the weight-loss drug sector, providing funding for future strategic acquisitions and ensuring the company maintains its competitive edge in a challenging market.
- New Product Potential: Eli Lilly's new drugs such as Ebglyss, Kisunla, and Jaypirca posted strong sales growth in the first quarter, and although they currently represent a small portion of total revenue, this trend is expected to continue with new approvals, further diversifying revenue sources.
- Pain Management Opportunity: STC-004, a non-opioid candidate for chronic pain treatment, targets a pain management market projected to be worth $90.5 billion, and if it progresses well, it could provide Eli Lilly with new growth drivers to counteract competition in the weight-loss market.
See More
Quantum Stocks Decline While Consumer Staples Rise
- Quantum Stocks Struggle: Quantinuum's debut on Nasdaq was lackluster, closing flat and subsequently dropping over 8% on Friday, falling below its IPO price of $60 per share, indicating market caution towards the quantum computing sector which may impact future funding and investor confidence.
- Consumer Staples Surge: Amid Friday's market sell-off, the consumer staples sector rose 2%, with companies like Colgate-Palmolive, Coca-Cola, and Procter & Gamble gaining over 3%, reflecting investor preference for defensive stocks, which could lead to a shift in capital towards these stable industries.
- Strong Performance in Medical Devices: Cooper Companies reported second-quarter adjusted earnings of $1.21 per share, exceeding the $1.10 consensus estimate, with revenue of $1.08 billion surpassing the $1.05 billion forecast, showcasing robust performance in the medical device sector that may attract more investor interest.
- Software Stocks Outlook Weakens: Docusign's outlook failed to impress, with shares slipping 6% as it projected second-quarter revenue between $865 million and $869 million, slightly below consensus, potentially affecting its future market performance and investor confidence.
See More
US Stocks Retreat as Tech Sector Faces Pressure
- Job Data Impact: Non-farm payrolls rose by 172,000 in May, exceeding expectations, while the unemployment rate held steady at 4.3%, leading to increased Treasury yields and heightened market expectations for a rate hike, negatively impacting stocks.
- Chip Stock Investment Opportunity: Jim Cramer highlighted that despite the tech sector's pullback, this presents a good opportunity to buy chip stocks, particularly Intel, which fell 6% on Friday, indicating that confidence in the sector remains strong.
- CrowdStrike Stock Decline: CrowdStrike's stock fell another 3.4% on Friday, with the CEO stating that expectations for earnings boosts from Anthropic's AI model are premature; Jim believes this pullback offers a buying opportunity for new investors, anticipating significant growth this quarter.
- Upcoming IPOs: SpaceX's IPO is set for next Friday, and although the S&P announced no index adjustments, Jim remains cautious about investors potentially selling existing holdings to make room for SpaceX, especially with Anthropic and OpenAI IPOs also on the horizon.
See More
GLP-1 Drugs Expected to Generate $150B in Global Sales by 2030
- Market Growth: TD Cowen estimates that global sales of GLP-1 drugs will reach $150 billion by 2030, reflecting an approximately 8% increase from the previous forecast of $139 billion made just over a year ago, indicating strong market growth potential.
- Increased Patient Beneficiaries: The forecast suggests that around 59 million patients could benefit from GLP-1 drugs by 2030, up from 46 million previously, highlighting a significant rise in demand for this class of medications.
- Oral Drug Market Share: Analysts project that oral GLP-1 drugs, which debuted in the U.S. this year, could account for 14% of total global GLP-1 sales by 2030, further driving market expansion.
- Intensified Competition: As pharmaceutical companies race to develop the next FDA-approved GLP-1 therapy through licensing deals and M&A, Lilly and Novo Nordisk are expected to maintain their dominance in the rapidly growing obesity drug market, with competitors like Pfizer and AstraZeneca also actively pursuing opportunities.
See More
TD Cowen Raises Global GLP-1 Sales Forecast Significantly
- Market Share Forecast: TD Cowen projects that Eli Lilly (LLY) and Novo Nordisk (NVO) will maintain market leadership with expected shares of 62% and 31%, respectively, highlighting their strong competitive positions in the GLP-1 treatment sector.
- Sales Growth Outlook: The firm raised its global GLP-1 sales forecast to $150 billion by 2030, significantly above the previous estimate of $139 billion, with around 59 million patients expected to use GLP-1 therapies by the decade's end, indicating robust market demand.
- Oral Therapy Market Competition: Oral GLP-1 drugs are expected to account for 14% of overall sales, up from 11%, reflecting intensifying competition between Novo and Lilly in the oral weight-loss treatment market, with Novo's Wegovy pill gaining an early advantage.
- Stock Performance Comparison: While NVO shares have declined approximately 15% this year, LLY's stock has risen by 4%, indicating a bullish sentiment towards LLY, particularly in light of its rapid expansion in the oncology sector.
See More
Eli Lilly Becomes First $1 Trillion Pharmaceutical Company
- GLP-1 Drug Expansion: Eli Lilly's Mounjaro and Zepbound have driven a 56% year-over-year revenue increase to $19.8 billion in Q1, with earnings per share soaring 156% to $8.55, indicating robust market demand in diabetes and obesity treatment.
- Acquisition to Broaden Portfolio: Lilly announced a $3.83 billion acquisition of three biotech firms, gaining promising drug candidates, including a $1.5 billion purchase of Curevo for a shingles vaccine, enhancing its product lineup significantly.
- Multiple Indication Development: While GLP-1 drugs are in the spotlight, Lilly's immunology, oncology, and neuroscience therapies saw a 160% revenue increase in Q1, with 42 phase 3 trials underway, anticipating several new therapies to launch soon.
- Strong Market Expectations: Lilly shares trade at a premium valuation of around 29 times projected earnings, reflecting expectations of sustained strong demand for GLP-1 drugs, with projected 2026 revenue between $82 billion and $85 billion, marking a 28% increase.
See More
Eli Lilly Accelerates Diversification Strategy with New Acquisitions
- New Asset Acquisitions: Eli Lilly's recent acquisitions of Curevo, LimmaTech Biologics, and Vaccine Company, with a total expected expenditure of up to $3.8 billion, will enhance its asset portfolio in infectious diseases, thereby reducing reliance on its core market.
- Strong Financial Performance: Over the past three years, Eli Lilly's free cash flow has significantly increased, partly due to its success in the weight-loss drug sector, providing funding for future strategic acquisitions and ensuring the company maintains its competitive edge in a challenging market.
- New Product Potential: Eli Lilly's new drugs such as Ebglyss, Kisunla, and Jaypirca posted strong sales growth in the first quarter, and although they currently represent a small portion of total revenue, this trend is expected to continue with new approvals, further diversifying revenue sources.
- Pain Management Opportunity: STC-004, a non-opioid candidate for chronic pain treatment, targets a pain management market projected to be worth $90.5 billion, and if it progresses well, it could provide Eli Lilly with new growth drivers to counteract competition in the weight-loss market.
See More
Quantum Stocks Decline While Consumer Staples Rise
- Quantum Stocks Struggle: Quantinuum's debut on Nasdaq was lackluster, closing flat and subsequently dropping over 8% on Friday, falling below its IPO price of $60 per share, indicating market caution towards the quantum computing sector which may impact future funding and investor confidence.
- Consumer Staples Surge: Amid Friday's market sell-off, the consumer staples sector rose 2%, with companies like Colgate-Palmolive, Coca-Cola, and Procter & Gamble gaining over 3%, reflecting investor preference for defensive stocks, which could lead to a shift in capital towards these stable industries.
- Strong Performance in Medical Devices: Cooper Companies reported second-quarter adjusted earnings of $1.21 per share, exceeding the $1.10 consensus estimate, with revenue of $1.08 billion surpassing the $1.05 billion forecast, showcasing robust performance in the medical device sector that may attract more investor interest.
- Software Stocks Outlook Weakens: Docusign's outlook failed to impress, with shares slipping 6% as it projected second-quarter revenue between $865 million and $869 million, slightly below consensus, potentially affecting its future market performance and investor confidence.
See More
US Stocks Retreat as Tech Sector Faces Pressure
- Job Data Impact: Non-farm payrolls rose by 172,000 in May, exceeding expectations, while the unemployment rate held steady at 4.3%, leading to increased Treasury yields and heightened market expectations for a rate hike, negatively impacting stocks.
- Chip Stock Investment Opportunity: Jim Cramer highlighted that despite the tech sector's pullback, this presents a good opportunity to buy chip stocks, particularly Intel, which fell 6% on Friday, indicating that confidence in the sector remains strong.
- CrowdStrike Stock Decline: CrowdStrike's stock fell another 3.4% on Friday, with the CEO stating that expectations for earnings boosts from Anthropic's AI model are premature; Jim believes this pullback offers a buying opportunity for new investors, anticipating significant growth this quarter.
- Upcoming IPOs: SpaceX's IPO is set for next Friday, and although the S&P announced no index adjustments, Jim remains cautious about investors potentially selling existing holdings to make room for SpaceX, especially with Anthropic and OpenAI IPOs also on the horizon.
See More
GLP-1 Drugs Expected to Generate $150B in Global Sales by 2030
- Market Growth: TD Cowen estimates that global sales of GLP-1 drugs will reach $150 billion by 2030, reflecting an approximately 8% increase from the previous forecast of $139 billion made just over a year ago, indicating strong market growth potential.
- Increased Patient Beneficiaries: The forecast suggests that around 59 million patients could benefit from GLP-1 drugs by 2030, up from 46 million previously, highlighting a significant rise in demand for this class of medications.
- Oral Drug Market Share: Analysts project that oral GLP-1 drugs, which debuted in the U.S. this year, could account for 14% of total global GLP-1 sales by 2030, further driving market expansion.
- Intensified Competition: As pharmaceutical companies race to develop the next FDA-approved GLP-1 therapy through licensing deals and M&A, Lilly and Novo Nordisk are expected to maintain their dominance in the rapidly growing obesity drug market, with competitors like Pfizer and AstraZeneca also actively pursuing opportunities.
See More
TD Cowen Raises Global GLP-1 Sales Forecast Significantly
- Market Share Forecast: TD Cowen projects that Eli Lilly (LLY) and Novo Nordisk (NVO) will maintain market leadership with expected shares of 62% and 31%, respectively, highlighting their strong competitive positions in the GLP-1 treatment sector.
- Sales Growth Outlook: The firm raised its global GLP-1 sales forecast to $150 billion by 2030, significantly above the previous estimate of $139 billion, with around 59 million patients expected to use GLP-1 therapies by the decade's end, indicating robust market demand.
- Oral Therapy Market Competition: Oral GLP-1 drugs are expected to account for 14% of overall sales, up from 11%, reflecting intensifying competition between Novo and Lilly in the oral weight-loss treatment market, with Novo's Wegovy pill gaining an early advantage.
- Stock Performance Comparison: While NVO shares have declined approximately 15% this year, LLY's stock has risen by 4%, indicating a bullish sentiment towards LLY, particularly in light of its rapid expansion in the oncology sector.
See More
